Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herbal Medicine Plus Antiviral Therapy for Chronic Hepatitis B Fibrosis (Real-World Cohort)
ChiCTR2600130293Phase 4Not yet recruiting
- Sponsor
- Shuguang Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir + amibufenamide, tenofovir alafenamide and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Shuguang Hospital. Primary endpoint: Change in FIB-4 index at 48 weeks (primary). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tenofovir + amibufenamidetenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600130293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130293.